XENETIC BIOSCIENCES, INC.

XBIO

CIK 0001534525 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$766K
↑+18.1% +$117Kvs FY2024 (Q4)
Gross Profit
$766K
↑+18.1% +$117Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Strong
65/100
  • Profitability
    0ROIC -33.4% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 8.32 (above 1.5 = solid)
  • Leverage
    100D/E -1.17 (under 0.5 = conservative)
  • Efficiency
    15Asset Turnover 0.39x (1.0+ = capital-efficient)
  • Growth
    77Revenue YoY +18.1% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -53.0% · trend +59.7pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
investment in PP&E
Stock-based comp (TTM)
$65K
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$8M
everything owned
Total liabilities
$968K
everything owed
Stockholders' equity
$7M
shareholder claim
Long-term debt
$213K
outstanding bonds + loans

Recent performance · 61 quarters

Revenue↑+18.1% +$117K
$766K
Net Income↓-16.8% -$73K
$-510K
Free Cash Flow↑+13.6% +$157K
$-1M
Operating Margin↑+28.3pts
-53.0%

Drill down